Alliance Global Partners downgraded Sensus Healthcare (NASDAQ:SRTS) to “neutral” and reduced its price target to $2.40 from $6, citing a first quarter earnings preview and model updates. The stock was quoted at $2.55...
Alliance Global Partners lowered its price target for Interpace Biosciences (NASDAQ:IDXG) to $9.25 from a reverse split-adjusted $21, but maintained its “buy” rating, after the company posted fourth quarter...
Alliance Global Partners downgraded Obalon Therapeutics (NASDAQ:OBLN) to “neutral” from “buy” and slashed its price target to 90 cents from $6.40 after the company moved to explore potential financial and strategic...
Alliance Global Partners lowered its price target for T2 Biosystems (NASDAQ:TTOO) to $1.10 from $1.80 after the company released lower than expected first quarter results but added a COVID-19 program to its platform...
Alliance Global Partners raised its price target for OpGen (NASDAQ:OPGN) to $5 from $2.50 after the company reported better than expected fourth quarter results. The stock closed at $2.99 on March 24. OpGen also...
Alliance Global Partners upgraded Sensus Healthcare (NASDAQ:SRTS) to “buy” from “neutral” with a price target of $6 after the company reported fourth quarter results. The stock closed at $4.62 on Feb. 13. Analyst Ben...
Alliance Global Partners lowered its price target for Motus GI Holdings (NASDAQ:MOTS) to $3.75 from $6, reflecting a lower sales multiple and reduced estimates after the company’s third quarter report. The stock closed...
Alliance Global Partners raised its price target for OpGen (NASDAQ:OPGN) to $11 from a reverse-split adjusted $8 after an analysis of its proposed merger with Curetis (Euronext:CURE), an infectious disease molecular...
Analysts for Alliance Global Partners and SVB Leerink raised their price targets for T2 Biosystems (NASDAQ:TTOO) following a conference call that updated multiple positive developments. Ben Haynor of AGP writes that the...
Alliance Global Partners initiated coverage of Itamar Medical (NASDAQ:ITMR) with a “buy” rating and $15.50 price target. The stock closed at $9.10 on Aug. 29. “We see Itamar as the technology leader in home sleep...